Idec Pharmaceuticals Corporation
Records under this name other than patents Idec Pharmaceuticals Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Idec Pharmaceuticals Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,157,276 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures Formerly held Term ended Term ended Jun 21, 2024 · USPTO record | Term ended | Term ended Jun 21, 2024 | USPTO record |
| US 7,220,356 | Method of Purifying Polypeptides by Simulated Moving Bed Chromatography Formerly held Term ended Term ended Sep 12, 2023 · High confidence | Term ended | Term ended Sep 12, 2023 | High confidence |
| US 7,319,139 | TAG-72 specific CH2 domain deleted antibodies Formerly held Term ended Term ended Jan 29, 2022 · USPTO record | Term ended | Term ended Jan 29, 2022 | USPTO record |
| US 8,329,172 | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody Formerly held Term ended Term ended Nov 15, 2021 · USPTO record | Term ended | Term ended Nov 15, 2021 | USPTO record |
| US 7,604,989 | Inhibition of apoptosis process and improvement of cell performance Formerly held Lapsed on the fee record Ended Oct 20, 2021 · USPTO record | Lapsed on the fee record | Ended Oct 20, 2021 | USPTO record |
| US 7,294,753 | Method for Preparing Anti-Mif Antibodies Formerly held Term ended Term ended Jun 3, 2021 · Medium confidence | Term ended | Term ended Jun 3, 2021 | Medium confidence |
| US 6,682,734 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Ended no later than Jan 27, 2021 · USPTO record | Term ended | Ended no later than Jan 27, 2021 | USPTO record |
| US 8,557,244 | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody Formerly held Term ended Ended no later than Jul 28, 2020 · USPTO record | Term ended | Ended no later than Jul 28, 2020 | USPTO record |
| US 9,504,744 | Treatment of Diffuse Large-Cell Lymphoma with ANTI-CD20 Antibody Formerly held Term ended Term ended Jul 28, 2020 · Medium confidence | Term ended | Term ended Jul 28, 2020 | Medium confidence |
| US 6,451,284 | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy Formerly held Term ended Term ended Jul 26, 2020 · USPTO record | Term ended | Term ended Jul 26, 2020 | USPTO record |